All In Biotech

Drug Trial Radar · NCT07760155

A Phase 2 Study on the Safety and Efficacy of the Anti-BAFF-R Monoclonal Antibody, ESG206, in Patients With Systemic Lupus Erythematosus

Last checked: Nov 19, 2026Latest source record: Aug 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

40

Planned (sponsor's estimate)

Start

Sep 1, 2026

Primary completion

Mar 31, 2028

Study completion Sep 30, 2028

Sponsor

Sponsor type
Industry
First posted
Aug 12, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, randomized, double-blind, placebo-controlled Phase II study designed to evaluate the efficacy and safety of ESG206 in participants with Systemic Lupus Erythematosus (SLE).

Conditions

  • Systemic Lupus Erythematosus (SLE)

Interventions

  • ESG206Drug

    Anti-BAFF-R Monoclonal Antibody

  • ESG206Drug

    Anti-BAFF-R Monoclonal Antibody

  • PlaceboDrug

    Placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. SLE Responder Index (SRI)-4 response rate at Week 25 compared with placeboTime frame: Up to approximately 25 weeks

Locations

20 sites in 1 country. Site status is shown where the registry gives one.

  • Shenzhen Third People's Hospital

    Shenzhen, Guangdong, China

  • Zhongshan Traditional Chinese Medicine Hospital

    Zhongshan, Guangdong, China

  • Second Affiliated Hospital of Guilin Medical University

    Guilin, Guangxi, China

  • Liupanshui Shougang Shuigang Hospital

    Liupanshui, Guizhou, China

  • Affiliated Hospital of Hebei Engineering University

    Handan, Hebei, China

  • Second Hospital of Hebei Medical University

    Shijiazhuang, Hebei, China

  • Changde First People's Hospital

    Changde, Hunan, China

  • Xiangya Hospital, Central South University

    Changsha, Hunan, China

  • Loudi Central Hospital

    Loudi, Hunan, China

  • Zhuzhou Central Hospital

    Zhuzhou, Hunan, China

  • Xuzhou Central Hospital

    Xuzhou, Jiangsu, China

  • Zibo Central Hospital

    Zibo, Shandong, China

  • Renji Hospital, Shanghai Jiao Tong University School of Medicine

    Shanghai, Shanghai Municipality, China

  • Shanghai Tongji Hospital

    Shanghai, Shanghai Municipality, China

  • Linfen Central Hospital

    Linfen, Shanxi, China

  • Mianyang Central Hospital

    Mianyang, Sichuan, China

  • Affiliated Hospital of North Sichuan Medical College

    Nanchong, Sichuan, China

  • Huzhou Third People's Hospital

    Huzhou, Zhejiang, China

  • Jinhua Municipal Central Hospital

    Jinhua, Zhejiang, China

  • Ningbo Medical Center Lihuili Hospital

    Ningbo, Zhejiang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.